Millions of people around the world suffer from diseases that have no approved treatments, and many promising therapies remain out of reach, waiting for approval. Patients and doctors face a slow, complex, and sometimes bewildering process to find clinical trials or special programs that provide access to these treatments before general approval.
myTomorrows was created to simplify this process by offering a global platform that connects patients, doctors, clinical trial sites, and pharmaceutical companies. This platform helps patients find and gain access to treatments still in development, improving transparency and reducing delays.
Today, myTomorrows raised $29 million in funding from the investment firm Avego to scale its AI-powered platform that connects patients, physicians, clinical trial sites, and BioPharma partners. The funding will also accelerate the company’s expansion into new markets, strengthen collaborations with the pharmaceutical industry, and enhance its real-world data capabilities.
“This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow’s therapies. Avego’s extensive expertise in life sciences, particularly BioPharma, will be instrumental as we scale our platform and broaden our impact across the global health landscape,” said Michel van Harten, CEO of myTomorrows.
Bridging the gap between science and access
The company was founded in 2012 by Ronald Brus, a physician and biotech entrepreneur who experienced firsthand the challenges of finding treatment options when his father was diagnosed with aggressive lung cancer. Driven by frustration and determination, Ronald started myTomorrows to create a faster, easier way for patients worldwide to access promising treatments.
Leadership today includes Michel van Harten, who joined as Medical Director in 2017 and now serves as CEO, bringing a blend of medical expertise and business acumen. Together, they share a mission to ensure patients everywhere have fair, unbiased access to emerging therapies, building a healthcare future defined by patient empowerment, transparency, and global reach.
Michel van Harten told TFN exclusively, “myTomorrows was founded to fix a broken system that makes accessing emerging treatments far too difficult. We’ve built an AI-powered platform that is transforming global treatment access by connecting patients, physicians, sites and BioPharma companies to make the discovery and access process faster, smarter, and more transparent. With this investment, we’re scaling a technology that’s setting a new global standard and positioning myTomorrows as the default gateway to tomorrow’s medicines.”
myTomorrows combines technology with human expertise to deliver clear pathways to investigational treatments. The platform uses advanced tools to search multiple global clinical trial registries, providing a unified overview that helps physicians quickly identify suitable programs for their patients. It integrates securely with electronic health records and complies with strict privacy regulations like GDPR and HIPAA, ensuring patient data remains protected.
Beyond technology, myTomorrows offers expert patient navigation, assisting with paperwork, referrals, and overcoming regulatory barriers that often slow access. The system is designed to accelerate clinical trial recruitment, reduce screening failures, and collect real-world data that supports drug approval processes and better patient outcomes.
Unlike MedaSystems or everyone.org, myTomorrows blends cutting-edge technology with personalised, hands-on support, creating a uniquely effective solution in the early access space.
What’s next?
With fresh funding from Avego, myTomorrows aims to scale globally by expanding user and pharma client bases and deepening collaborations with pharmaceutical companies. The company is developing new capabilities to automate parts of the patient and physician journey for greater efficiency and aims to integrate seamlessly with healthcare systems worldwide.
